These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26450371)

  • 21. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.
    Somasundaram R; Villanueva J; Herlyn M
    Adv Pharmacol; 2012; 65():335-59. PubMed ID: 22959031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in targeted therapy for melanoma.
    Friedlander P; Hodi FS
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):619-27. PubMed ID: 21157411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular alterations in melanoma and targeted therapies].
    Mourah S; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S5-S11. PubMed ID: 25776766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for metastatic melanoma: time for a change?
    Gogas HJ; Kirkwood JM; Sondak VK
    Cancer; 2007 Feb; 109(3):455-64. PubMed ID: 17200963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted therapy resistance mechanisms and therapeutic implications in melanoma.
    Chen G; Davies MA
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):523-36. PubMed ID: 24880945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combinatorial approach to treatment of melanoma.
    Ashworth MT; Daud AI
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):601-12. PubMed ID: 24880950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
    Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
    Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular drivers of cellular metabolic reprogramming in melanoma.
    Abildgaard C; Guldberg P
    Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma.
    Almeida FV; Douglass SM; Fane ME; Weeraratna AT
    Pigment Cell Melanoma Res; 2019 Mar; 32(2):237-247. PubMed ID: 30216694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistance in human melanoma.
    Helmbach H; Rossmann E; Kern MA; Schadendorf D
    Int J Cancer; 2001 Sep; 93(5):617-22. PubMed ID: 11477569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opportunities and challenges in the development of experimental drug combinations for cancer.
    Humphrey RW; Brockway-Lunardi LM; Bonk DT; Dohoney KM; Doroshow JH; Meech SJ; Ratain MJ; Topalian SL; Pardoll DM
    J Natl Cancer Inst; 2011 Aug; 103(16):1222-6. PubMed ID: 21765011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2.
    Pak BJ; Chu W; Lu SJ; Kerbel RS; Ben-David Y
    Cancer Metastasis Rev; 2001; 20(1-2):27-32. PubMed ID: 11831643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy- An emerging target for melanoma therapy.
    Ndoye A; Weeraratna AT
    F1000Res; 2016; 5():. PubMed ID: 27583134
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications.
    Fischer GM; Vashisht Gopal YN; McQuade JL; Peng W; DeBerardinis RJ; Davies MA
    Pigment Cell Melanoma Res; 2018 Jan; 31(1):11-30. PubMed ID: 29049843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: Antitarget Therapies: New Frontiers in the Treatment of Cancer.
    Festuccia C; Lodola A; Gravina GL
    Anticancer Agents Med Chem; 2016; 16(1):4-6. PubMed ID: 26350030
    [No Abstract]   [Full Text] [Related]  

  • 37. Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma.
    Demirsoy S; Martin S; Maes H; Agostinis P
    Front Oncol; 2016; 6():240. PubMed ID: 27896217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Update on the Role of Ubiquitination in Melanoma Development and Therapies.
    Soysouvanh F; Giuliano S; Habel N; El-Hachem N; Pisibon C; Bertolotto C; Ballotti R
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33800394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current State of Animal (Mouse) Modeling in Melanoma Research.
    Kuzu OF; Nguyen FD; Noory MA; Sharma A
    Cancer Growth Metastasis; 2015; 8(Suppl 1):81-94. PubMed ID: 26483610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death.
    Tortelli TC; de Godoy LMF; de Souza GA; Bonatto D; Otake AH; de Freitas Saito R; Rosa JC; Greene LJ; Chammas R
    Oncotarget; 2017 Jun; 8(26):43114-43129. PubMed ID: 28562344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.